Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04152265
Other study ID # 6/2019
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 1, 2019
Est. completion date December 31, 2020

Study information

Verified date November 2019
Source University of Warmia and Mazury in Olsztyn
Contact Tomasz Sawicki, PhD
Phone +48 89 524 55 19
Email tomasz.sawicki@uwm.edu.pl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is the determination of the zearalenone and its metabolites (α and β) level in the blood plasma and faeces of patients at increased risk of cancer, in relation to the nutrition data (FFQ) and information on the quality of life dependent on health (WHOQOL-BREF).

The study is performer within the framework of the Polish Colonoscopy Screening Program. Within the study 100 volunteers between 50 and 65 years of age. while, the colonoscopies will be performed in Provincial Specialist Hospital in Olsztyn. Patients with positive test result, who have been diagnosed with polyps or cancer, will be assigned to risk group. The study has been approved by a local bioethics committee.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 65 Years
Eligibility Inclusion Criteria:

- Men and women aged from 50 to 65 years residing in Poland.

Exclusion Criteria:

- subjects requiring long-term care due to somatic, mental retardation or other mental illness.

- history of colorectal resection.

Study Design


Intervention

Procedure:
colonoscopy
colonoscopy
Other:
questionnaires
complete the two questionnaires (Food Frequency Questionnaire (FFQ) and the questionnaire of The World Health Organization Quality of Life (WHOQOL-BREF)
demographic data collections
completing the demographic questionnaire
anthropometric data collections
For the determination of anthropometric data will be used a professional body mass composition analyser (Seca,Hamburg, Germany)
Procedure:
Collecte the biological samples
blood and faeces collections

Locations

Country Name City State
Poland Provincial Specialist Hospital in Olsztyn Olsztyn

Sponsors (3)

Lead Sponsor Collaborator
University of Warmia and Mazury in Olsztyn Ministry of Health Republic of Poland, Provincial Specialist Hospital in Olsztyn

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Completion of the assigned screening strategy Completion of the assigned screening strategy within 8 weeks of enrollment defined as:
* current screening strategy: documented screening colonoscopy.
Within 8 weeks of enrollment
Secondary Analysis of the concentration of the mycotoxin Determination of the concentration and a profile of the mycotoxin using the high-performance liquid chromatography coupled with the mass spectrometry (HPLC-MS) 5 month
Secondary Characteristics of gut bacterial The presence of bacterial DNA in the samples will be confirmed using real-time polymerase chain reaction (RT-PCR). Microbial diversity will be study by sequencing the amplified V3-V4 region of the 16S rRNA gene by using primers 16S. Next, the amplicon pools will be prepared for sequencing and the size and quantity of the amplicon library will be assessed on NGS MiSeq. 6 month
Secondary Determination of anthropometric data The anthropometric data will be determined using the professional body mass composition analyser. Based on the obtained data will be calculated Body Mass Index (BMI), which will be expressed in kg/m^2 4 weeks